Back to Pharma & Healthcare
Endologix to Present at Three Upcoming Conferences

IRVINE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences. The first presentation will be at the Canaccord Adams 3rd Annual Cardiovascular Conference at the Nikko Hotel in San Francisco, CA.

         Event:  Canaccord Adams 3rd Annual Cardiovascular Conference
         Date:   Tuesday, November 10, 2009
         Time:   11:00 a.m. PT

The second presentation will be at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City.

         Event:  Lazard Capital Markets 6th Annual Healthcare Conference
         Date:   Wednesday, November 18, 2009
         Time:   10:00 a.m. ET

The third presentation will be at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City.

         Event:  Piper Jaffray 21st Annual Health Care Conference
         Date:   Tuesday, December 1, 2009
         Time:   2:30 p.m. ET

An audio Web cast of the Company's presentations will be available by visiting the investor relations section of Endologix's Web site at www.endologix.com. A replay of the presentations will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com

    COMPANY CONTACT:                  INVESTOR CONTACTS:
    ----------------                  ------------------
    Endologix, Inc.                   The Ruth Group
    John McDermott, CEO               Nick Laudico (646) 536-7030
    (949) 595-7200                    Zack Kubow (646) 536-7020
    www.endologix.com

SOURCE Endologix, Inc.

Copyright (2009) PR Newswire. All Rights Reserved.
Back to Pharma & Healthcare
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki